• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Herpes Simplex Virus 1 (HSV-1)-Based Vectors

        互联网

        3004
        Herpes simplex virus type 1 (HSV-1) is a neurotropic virus displaying several outstanding adaptations to the nervous system, and each of them can be rationally exploited in the design of gene therapy vectors with regard to neurological applications. Replication-competent attenuated vectors are becoming a suitable and powerful tool to eradicate brain tumors, such as malignant gliomas, due to their ability to replicate and spread only within the tumor mass, and have reached Phase II clinical trials in some cases. Replication-incompetent recombinant vectors are nontoxic gene transfer tools that preserve most of the neurotropic features of HSV-1, particularly the ability to express genes after having established latent infections, and are thus proficient candidates for therapeutic gene transfer settings in neurons. A first clinical trial, conceived to treat cancer-related pain, is currently being developed. Helper-dependent amplicon vectors take advantage of the capacity of the virus particle to accommodate up to 150 kbp of foreign DNA, enabling these vectors to deliver complete genomic loci to the nucleus of mammalian cells and making amplicons particularly useful in protocols where stable and physiological transgene expression is required. However, difficulties in obtaining large stocks of helper-free amplicons are hampering the use of these vectors in the clinic. This chapter summarizes current applications of HSV-1-based vectors with particular emphasis in amplicon vectors.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序